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Abstract: A large percentage of primary sensory neurons in the trigeminal ganglia (TG) contain
neuropeptides such as tachykinins or calcitonin gene-related peptide. Neuropeptides released from
the central terminals of primary afferents sensitize the secondary nociceptive neurons in the trigeminal
nucleus caudalis (TNC), but also activate glial cells contributing to neuroinflammation and consequent
sensitization in chronic orofacial pain and migraine. In the present study, we investigated the newest
member of the tachykinin family, hemokinin-1 (HK-1) encoded by the Tac4 gene in the trigeminal
system. HK-1 had been shown to participate in inflammation and hyperalgesia in various models,
but its role has not been investigated in orofacial pain or headache. In the complete Freund’s adjuvant
(CFA)-induced inflammatory orofacial pain model, we showed that Tac4 expression increased in the
TG in response to inflammation. Duration-dependent Tac4 upregulation was associated with the
extent of the facial allodynia. Tac4 was detected in both TG neurons and satellite glial cells (SGC)
by the ultrasensitive RNAscope in situ hybridization. We also compared gene expression changes
of selected neuronal and glial sensitization and neuroinflammation markers between wild-type
and Tac4-deficient (Tac4-/-) mice. Expression of the SGC/astrocyte marker in the TG and TNC was
significantly lower in intact and saline/CFA-treated Tac4-/- mice. The procedural stress-related increase
of the SGC/astrocyte marker was also strongly attenuated in Tac4-/- mice. Analysis of TG samples
with a mouse neuroinflammation panel of 770 genes revealed that regulation of microglia and
cytotoxic cell-related genes were significantly different in saline-treated Tac4-/- mice compared to
their wild-types. It is concluded that HK-1 may participate in neuron-glia interactions both under
physiological and inflammatory conditions and mediate pain in the trigeminal system.
Keywords: orofacial pain; hemokinin-1; trigeminal ganglia; complete Freund’s adjuvant;
macrophages; satellite glial cells; neuroinflammation
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1. Introduction
Sensitization of trigeminal nociceptors by inflammatory mediators is a major factor of orofacial
pain and headache disorders by causing hyperalgesia and allodynia. The orofacial area is mainly
innervated by ophthalmic, maxillary and mandibular branches of the trigeminal nerve. The cell bodies
of the primary sensory neurons are located in the trigeminal ganglia (TG) and their central terminals
relay the protopathic information to the spinal trigeminal nucleus caudalis (TNC) and the upper
cervical dorsal horn. When trigeminal nerve injury or orofacial inflammation occurs, TG neurons
become sensitized and in turn release several mediators, which lead to enhanced responsiveness of the
secondary afferent neurons. Satellite glial cells (SGC) and resident macrophages in the TG, as well as
astrocytes and microglia in the central nervous system, are also activated in the process and contribute
to the sensitization. There is growing evidence that the cross-talk between neurons and glial cells has
a prominent modulatory role on nociceptive transmission under physiological and pathophysiological
conditions [1–6].
A major percentage of nociceptive sensory neurons both in the trigeminal and dorsal root
ganglia are peptidergic and release several neuropeptides, such as tachykinins (substance P (SP) and
neurokinins) and calcitonin gene-related peptide (CGRP) in response to activation [7,8]. Tachykinins
can be released both from the peripheral and central endings of primary sensory neurons contributing
to inflammatory processes and pain transmission [9,10]. The biological actions of tachykinins are
mediated by the G-protein coupled neurokinin NK-1, NK-2 and NK-3 receptors [11,12]. NK-1 receptor
antagonists were shown to effectively reduce neuropathic mechanical hyperalgesia and inflammatory
pain in animal models [13–15]. Since SP is expressed by trigeminal sensory neurons, it also became
the focus of migraine studies. SP released from the peripheral terminals of trigeminal neurons
induces plasma protein extravasation and vasodilatation in the dura mater [16], while centrally in
the TNC it contributes to pain transmission [17,18]. It has been shown that the SP/NK-1 system
participates in orofacial heat hyperalgesia in inflammatory and nerve injury-related animal models [19].
Preclinical data were promising regarding the use of NK-1 receptor antagonists in several pain
conditions and inflammatory disease models [19–21]. Nevertheless, human studies could not prove the
analgesic effect of these compounds, either in migraine [22–25] or in other conditions like post-operative
dental pain [26] or neuropathic pain [27]. The explanation for the failure of NK-1 receptor antagonists
as analgesics and anti-migraine drugs remains unclear, but it might be due to differences of the human
NK-1 receptor structure and function as compared to the rodent receptor, or the ineffectiveness of
competitively blocking the SP binding site [28,29].
The discovery of the newest member of the tachykinin family, the hemokinin-1 (HK-1) encoded
by the Tac4 gene [30], has given a new impetus to tachykinin research. HK-1 might be a novel key
molecule in behavior, pain and inflammatory processes [31]. There is a growing amount of data
regarding the mRNA expression of the Tac4 gene both in the central and peripheral nervous systems.
In contrast to other tachykinin members, relatively high expression of the Tac4 gene can be found in
the periphery (e.g., lung, spleen, adrenal gland). B and T lymphocytes, macrophages and dendritic
cells also express Tac4 [30,32–34]. While other tachykinins are conserved across mammals, HK-1 is
highly homologous in mouse and rat, but not in humans. Both rodent peptides and the human
HK-1 can bind to the NK-1 tachykinin receptor [35], but they also have distinct, NK-1-independent
actions [36,37]. Since the structures of HK-1 and SP are very similar, it is difficult to proceed with peptide
detection, localization and measurement. Although a few studies reported antibody development
(e.g., [38]) or a recent immunohistochemical study on the TG with an in-house developed antibody [39],
there are still no commercially available antibodies against HK-1. Despite the structural similarities and
common receptors of HK-1 and SP, some of their functions appear to be different, even opposing each
other [36,40–43]. This could be explained by different binding sites and different signalling pathways
by HK-1 compared to SP even at the NK-1 receptor, but a specific target is suggested to mediate several
actions of HK-1 [36]. Therefore, since the receptorial mechanisms of HK-1 are not precisely known,
pharmacological interventions (e.g., antagonists) cannot be used to validate the target.
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Studies investigating the pain modulatory function of HK-1 showed opposing effects,
pointing to a complex role of the peptide. HK-1 had a pronociceptive effect after intrathecal
or intracerebroventricular administration, causing pain and scratching behavior without influencing the
withdrawal latency to a noxious heat stimulus [34,43]. However, in other studies, an analgesic effect was
shown upon intracerebroventricular injection [44–46]. Its potential contribution to pain sensitization
was shown by the upregulation of Tac4 mRNA expression in lipopolysaccharide-stimulated cultured
microglia [47], and in the rat spinal dorsal horn after complete Freund’s adjuvant (CFA)-induced paw
inflammation [48].
The role of HK-1 in orofacial pain and trigeminal sensitization have been poorly investigated.
Therefore, we aimed to explore the potential role of HK-1 in the trigeminovascular system by (i) detecting
expression changes of Tac4 in the TG and TNC in a rat inflammatory orofacial pain model [49] (ii)
investigating behavioral alterations and gene expression changes of selected markers of neuronal
sensitization and neuroinflammation by comparing Tac4-deficient (Tac4-/-) and wild-type mice.
2. Results
2.1. Tac4 mRNA Levels Are Upregulated in Response to CFA-Induced Inflammation in the Rat TG in
Association with Facial Allodynia
The facial mechanonociceptive threshold of CFA-injected rats was significantly decreased
compared to saline injection, starting from day one until day seven after injection. The allodynia
reached its maximum on day three in the whisker pad area (Figure 1a), in accordance with our previous
results [49]. Tac4 mRNA expression was also measured in peripheral blood mononuclear cells (PBMCs),
TG and TNC tissues. The fold changes of Tac4 mRNA in TG (Figure 1b) followed the course of von
Frey threshold changes, reaching its maximum on day three. In TNC and PBMC samples the Tac4
expression could not be detected with sufficient reliability with this method, as Cq values were very
close to the detection limit.
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Figure 1. (a) Changes in mechanical threshold measured with von Frey filaments on day 1, 3, 7 after 
unilateral injection of complete Freund’s adjuvant (CFA) or saline (50 μL s.c.). Data are means ± S.E.M. 
(CFA: n = 5–16, saline: n = 6). A sterisks denote statistically significant differences between the control 
day and the days after CFA treatment (*** p ≤ 0.001, **** p ≤ 0.0001), while hash marks label statistically 
significant differences between saline and CFA groups (## p ≤ 0.01, ### p ≤ 0.001, #### p ≤ 0.0001) as 
analyzed by two-way ANOVA followed by Tukey’s multiple comparison tests; (b) time course of 
normalized fold changes in Tac4 mRNA expression of rat trigeminal ganglia (TG) on day 1, 3 and 7 
after CFA or saline injection. The mRNA levels were normalized to β2m and Hprt1. Data are means ± 
S.E.M. (n = 3 at each time point). Asterisks denote statistically significant differences between saline 
and CFA groups (*** p ≤ 0.001, **** p ≤ 0.0001), as analyzed by one-way ANOVA followed by Tukey’s 
multiple comparison tests. 
Figure 1. (a) Changes in mechanical threshold measured with von Frey filaments on day 1, 3, 7 after
unilateral injection of complete Freund’s adjuvant (CFA) or saline (50 µL s.c.). Data are means ± S.E.M.
(CFA: n = 5–16, saline: n = 6). A sterisks denote statistically significant differences between the control
day and the days after CFA treatment (*** p ≤ 0.001, **** p ≤ 0.0001), while hash marks label statistically
significant differences between saline and CFA groups (## p ≤ 0.01, ### p ≤ 0.001, #### p ≤ 0.0001)
as analyzed by t o-way ANOVA followed by Tukey’s multiple comparison tests; (b) time course of
normalized fold changes in Tac4 mRNA expression of rat trigeminal ganglia (TG) on day 1, 3 and 7
after CFA or saline injection. The mRNA levels were normalized to β2m and Hprt1. Data are means ±
S.E.M. (n = 3 at each time point). Asterisks denote statistically significant differences between saline
and CFA groups (*** p ≤ 0.001, **** p ≤ 0.0001), as analyzed by one-way ANOVA followed by Tukey’s
multiple comparison tests.
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2.2. CFA-Induced Orofacial Inflammation Upregulates Tac4 mRNA in Both Primary Sensory Neurons and
SGCs of the Rat TG
To investigate the basal expression and inflammation-induced alterations of the Tac4 mRNA in
the rat TG, fluorescent RNAscope in situ hybridization (ISH) was performed, that provides cellular
resolution and tissue context. Tac4 transcripts were localized primarily on sensory neurons and
SGCs in saline-treated samples (Figure 2a, left panel) and significantly upregulated in both cell
types upon CFA treatment (Figure 2a, right panel). Basal and elevated Tac4 mRNA levels were
analyzed semi-quantitatively using ImageJ software and plotted as Tac4-specific total dot area/number
detected in sensory neuron soma or SGC (Figure 2b). Sensory neurons and SGCs were identified
morphologically (see arrows and arrowheads, respectively, Figure 2a) and histologically by colocalizing
Tac4 with neuronal (NeuN, encoded by Rbfox3) and satellite glial marker (SK3, encoded by Kcnn3,
see Supplementary Figure S2). RNAscope performed on rat TG was validated by RNAscope 3-plex
negative control probes designed to bacterial dapB gene giving no detectable fluorescent signal on
any channel (Supplementary Figure S3a,b). RNAscope 3-plex mouse positive control probes were
used to visualize the housekeeping genes: RNA polymerase II subunit A (Polr2a), peptidyl-prolyl
cis-trans isomerase B (Ppib) and polyubiquitin-C (Ubc) mRNA on rat TG from saline-treated animals
(Supplementary Figure S3c,d).
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Figure 2. (a) Representative confocal images of Tac4 mRNA (red) counterstained with DAPI are shown
on longitudinal slices of rat TG after injection of saline or CFA. Arrows indicate sensory neurons,
arrowheads refer to SGCs. Scale bar: 50 µm, inset scale bar: 20 µm; (b) quantification of Tac4 mRNA
showing upregulation after CFA compared to saline injection in Tac4-positive neurons and SGCs of
n = 4 (saline)-6 (CFA) rats/group. Asterisks denote statistically significant differences between saline
and CFA groups (* p ≤ 0.05, ** p ≤ 0.01), as analyzed by Student’s t-test for unpaired samples. ROI:
region of interest; unit of the area: µm2.
2.3. CFA-Induced Orofacial Inflammation Upregulates Tac4 mRNA in Both Primary Sensory Neurons and
SGCs of the Mouse TG
Similarly to Tac4 expression found in rat TG, basal Tac4 mRNA was detected both in sensory
neurons and SGCs of the mouse TG (Figure 3a, left panel). Also, mouse Tac4 mRNA was shown to
be upregulated in response to CFA-induced inflammation (Figure 3a, right panel). Sensory neurons
and SGCs were identified morphologically (see arrows and arrowheads, respectively, Figure 3a).
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Technical control conditions using 3-plex negative (Supplementary Figure S3c) and mouse 3-plex
positive (Supplementary Figure S3d) control probes were applied on longitudinal mouse TG from
saline-injected animals.
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2.4. CFA-Induced Alterations of Neuronal and Glial Activation Markers in the TG and TNC of Tac4
Gene-Deficient Mice
Mouse TG samples exhibited a relatively low value of Tac4 expression levels, thus it could not be
relia ly detecte and evaluated by RT-qPCR. We wer unable to evaluate T c4 expr ssion in TNC and
PBMC samples either, similarly to rat TNC and PBMC samples.
We have pr viously described the gene activity profile of neuronal nd glia ctivation markers in
the rat TG and TNC, therefore w investigated the same markers in th mouse samples after orofacial
inflamm tion. In wild-type (WT) mice, neuronal FosB gene expressio was significantly upregulated
by day 3 compared to intact samples (data not shown). However, not only CFA injection but also
saline treatment caused an elevation of FosB in TG, therefore the differences between respective saline-
and CFA-treated groups were not significant by days 3 and 7. A significant upregulation of the
neuronal activation marker was only detected in Tac4-/- animals at a later time point, in day 7 samples.
Comparison of matching WT and Tac4-/- animal groups showed that upregulation of the neuronal
activation marker on days 3 and 7 was significantly lower in the TG of Tac4-/- mice (Figure 4a). In TNC
only minor differences were seen (Figure 4b).
In both TG (relative fold change WT: 1.00 ± 0.03 vs. Tac4-/-: 0.49 ± 0.03, p < 0.0001) and TNC
(relative fold change WT: 1.00 ± 0.03 vs. Tac4-/-: 0.82 ± 0.02, p < 0.001) samples of intact animals,
the microglia/macrophage activation marker (Iba1) showed significantly lower expression levels in
Tac4-/- mice compared to WTs. Iba1 expression was slightly higher in both saline- and CFA-treated Tac4-/-
mice compared to their corresponding WT groups, being significant on day 1 and 3 in the TG and
day 7 in the TNC. However, these differences were probably too small to be biologically meaningful
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(Figure 4c,d). The SGC/astrocyte activation marker Gfap was also expressed at a significantly lower
level in the TG (relative fold change WT: 1.00 ± 0.16 vs. Tac4-/-: 0.33 ± 0.06, p < 0.01) and TNC (relative
fold change WT: 1.00 ± 0.03 vs. Tac4-/-: 0.16 ± 0.05, p < 0.0001) of intact Tac4-/- compared to WT animals.
After treatment, Gfap expression increased in all groups on all days compared to an intact group (data
not shown). The effect of CFA on Gfap gene expression was a significant elevation in WT compared to
the respective saline-treated group on day 1 and 3, but not in TNC samples. Moreover, Gfap levels
were not altered due to CFA treatment in Tac4-/- mice. Gfap mRNA was decreased in all Tac4-/- groups
compared to the WT group in most of the comparisons, both in TG and TNC (Figure 4e,f).
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 22 
 
fold change WT: 1.00 ± 0.03 vs. Tac4-/-: 0.16 ± 0.05, p < 0.0001) of intact Tac4-/- compared to WT animals. 
After treatment, Gfap expression increased in all groups on all days compared to an intact group (data 
not shown). The effect of CFA on Gfap gene expression was a significant elevation in WT compa ed 
to the respective saline-treated group on day 1 and 3, but not in TNC samples. Moreover, Gfap levels 
were not altered due to CFA treatment in Tac4-/- mice. Gfap mRNA was decreased in all Tac4-/- groups 
compared to the WT group in most of the comparisons, both in TG and TNC (Figure 4e,f). 
 
Figure 4. Time course of normalized fold changes in FosB (A,B), Iba1 (C,D), Gfap (E,F) mRNA 
expression in the trigeminal ganglia (A,C,D) and trigeminal nucleus caudalis (B,D,F) of wild-type 
(WT) and Tac4-/- mice one, 3 and 7 days after saline/CFA injection. The mRNA levels were normalized 
to Ppia (TG) and Ppia, Gapdh (TNC), as detailed in Materials and methods. Data are means ± S.E.M. 
Figure 4. Time course of normalized fold changes in FosB (A,B), Iba1 (C,D), Gfap (E,F) mRNA expression
in the trig minal ganglia (A,C,D) and trigeminal ucleus caudalis (B,D,F) of wild-type (WT) and Tac4-/-
mice one, 3 and 7 days after saline/CFA injection. The mRNA levels were normalized to Ppia (TG)
and Ppia, Gapdh (TNC), as detailed in Materials and methods. Data are means ± S.E.M. (WT CFA: n =
3–10, WT saline: n = 4–9, Tac4-/- CFA: n = 5–7, Tac4-/- saline: n = 5–10). Asterisks denote statistically
significant differences between saline and CFA treated groups (* p ≤ 0.05, *** p ≤ 0.001), hash marks label
statistically significant differences between WT and Tac4-/- groups (# p ≤ 0.05, ## p ≤ 0.01, ### p ≤ 0.001,
#### p ≤ 0.0001), as analyzed by two-way ANOVA followed by Tukey’s multiple comparison tests.
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2.5. Neuroinflammation-Related Genes Are Differently Regulated between Saline-or CFA-Treated Tac4-/- and
WT Mice
Nanostring results revealed differentially expressed genes, as well as statistically significant
correlations of cell-type-specific gene expressions. In TG samples of saline-treated Tac4-/- mice,
15 genes were found to be differentially expressed with a p-value threshold of 0.05 when compared to
saline-treated WT mice. Nine genes were upregulated, six were downregulated in the Tac4-/- TG samples
(Figure 5). There were gene expression differences in saline-treated (non-inflamed control) animals in
case of genetic lack of HK-1 in the KO mice in comparison with WTs. Changes in microglia/macrophage
and cytotoxic cell-specific genes were significantly correlated when saline-treated Tac4-/- mice were
compared to saline-treated WTs (Figure 6). In TG samples of CFA-treated Tac4-/- mice, 22 genes were
found to be differentially expressed with a p-value threshold of 0.05 when compared to CFA-treated
WT animals. Thirteen genes were upregulated, 9 were downregulated in the Tac4-/- TG samples
(Figure 7). Changes in genes specific to neutrophil granulocytes were significantly correlated when
CFA-treated Tac4-/- mice were compared to CFA-treated WTs (Figure 8). For a further description of
other comparisons between groups, see Supplementary Material (Supplementary Figures S4–S7).
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Figure 5. Heat map representation of the differentially expressed genes with annotations between
TG samples of saline-treated Tac4-/- and WT mice. Rows represent genes and columns represent TG
samples (n = 3 in each group). Normalized gene counts data are shown as row-wise z-scores (scale is
shown on legend). Rows and columns were hierarchically clustered using Pearson correlation distance
measure and average method. Distances are shown as dendrograms. References for the functional
annotations: Cp [50] Pecam1 [51] Gdpd2 [52] Crip1 [53] Nlgn2 [54] Pdpn [55] Mdm2 [56] Dnmt1 [57]
Itga7 [58] Rapgef3 [59] Spp1 [60] Cidea [61] Tm4sf1 [62] Kcnj10 [63] Rps9 [63].
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Reln [77] Fgf13 [78–81] Cdc25a [82] Il1r2 [83] Plxdc2 [84] Tmem100 [85,86] Fancd2 [87] Gpr62 [88,89]
Bcl2l1 [90] Kmt2c [91] Slfn8 [92,93] Cflar [94].
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3. Discussion
In the present study, we confirmed the presence of Tac4 mRNA in the TG and established its
upregulation in response to orofacial inflammation. While it had been previously shown that HK-1
was expressed widely in the nervous system including the brain, spinal cord, dorsal root ganglia,
brain stem and the TG [34,39], this is the first study to assess the changes of Tac4 expression alterations
under pathological conditions. HK-1 had only been detected in small and medium-size neurons by
immunohistochemistry in the rat TG [39], but in the present study, we showed that besides the neuronal
expression, Tac4 mRNA was also expressed in satellite glial cells of the TG. More importantly, significant
inflammation-related upregulation of Tac4 was shown in both neurons and satellite glial cells. Based on
our facial mechanonociceptive threshold measurements and the qPCR results in the rat, we showed that
Tac4 upregulation occurred parallel to the development of allodynia, which suggests its potential role
in the sensitization process. Although we provide evidence for expression changes only at mRNA level,
which is a clear limitation of the study, the concomitant behavioral alterations suggest that the protein
products of the examined mRNAs were also affected. Without the availability of specific and sensitive
antibody against HK-1, we cannot further confirm it experimentally. The concomitant upregulation of
HK-1 in trigeminal sensory neurons and SGCs is of particular importance, since an increasing amount
of evidence points to the importance of neuron-glia crosstalk in chronic pain conditions, including
orofacial pain [2,6,95–98]. Other neuropeptides released from peptidergic sensory neurons have already
been suggested to have a prominent role in glial cell activation during sensitization. Among these,
CGRP, which has a clinically proven role in migraine headaches [99], appears to be a key mediator
of the neuron-glia interactions in the TG [4,100,101]. HK-1 could be a neuropeptide participating in
two-way communication between sensory neurons and satellite glial cells. Moreover, we have also
provided evidence on a possible physiological role of HK-1 in the trigeminal system by showing that
there is a baseline difference in the expression of genes associated with glial cell activity in both the TG
and the TNC.
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Previous studies by our and other groups have established that HK-1 contributes to the
development of hyperalgesia in both acute and chronic pain models. HK-1 can elicit pain when injected
intrathecally [34,43], and Tac4-/- mice have reduced nocifensive behavior in chemically-induced pain
and suppressed hyperalgesia/allodynia in chronic inflammatory and neuropathic pain models [41,102].
In inflammatory pain and arthritis, a pro-inflammatory component is also likely to contribute to
its action, since HK-1 expression was described in the immune system as well [30,33,103] and Tac4
deficiency also alleviated experimental lung inflammation [42]. On the other hand, HK-1 was shown
to have a direct role in central nociceptive sensitization, as spinal microglia and astrocyte activation
was also attenuated in Tac4-/- mice after nerve injury [41]. HK-1 is a potent NK-1 receptor agonist [34],
and most of its effects can be explained by NK-1 receptor activation. However, several lines of evidence
point to a different mechanism of action compared to SP, and even a yet unknown target. This is
supported by the observations that the phenotype of Tac4-/- deficient mice in chronic pain models is
different from SP or NK-1 receptor-deficient mice and an opposite phenotype was also described in
models of anxiety and depression as well [40].
We also investigated the contribution of HK-1 in trigeminal sensitization by adapting the
CFA-induced orofacial pain model to mice to compare the allodynia and the changes of neuronal
and glial activation markers between Tac4-/- and wild-type mice. In parallel, we confirmed the
upregulation of Tac4 in mice after inflammation by the ultrasensitive RNAscope technology [104].
However, RT-qPCR could detect neither basal nor upregulated Tac4 in mice, probably owing to a low
expression and the small tissue volume. Lamentably, we could not unequivocally show that orofacial
allodynia was attenuated in Tac4-/- mice in the present study (Supplementary Figure S1a). The lack
of clear behavioral functional data for the Tac4-/- phenotype in this model is another limitation of
our study. This technical issue is likely the light restraint that had to be used to measure the von
Frey threshold of the face, which appeared to be an important stress factor. In contrast with rats,
mice do not adapt well to repeated handling [105], therefore we tried to limit the handling and the
number of repeated measurements to the minimum. Despite this, the mice were probably too stressed
during the experiment, which could be one of the reasons that the mechanical thresholds of both
saline and CFA-treated animals decreased from the baseline. It is also worth mentioning that based on
our unpublished observations already the baseline von Frey threshold values of C57Bl/6 mice were
very low compared to the threshold of NMRI mice, which usually show lower anxiety level in our
experience. Stress-induced hyperalgesia is a well-known phenomenon which is both detectable in
humans and animal models [106]. Other researchers use special restrainers or cages to measure the
orofacial thresholds in mice to overcome the challenges of handling-induced stress [107,108]. We have
previously used the technique in NMRI mice [109], but in our experience C57Bl/6 mice tolerated
this type of restraint less compared to the light manual handling. Changes in spontaneous behavior
measured in the open field test corroborated previous results of our group regarding the possible role
of HK-1 in mediating anxiolytic actions [40], but we could not detect any pain-induced reduction of
spontaneous activity either (Supplementary Figure S1b).
Our previous results in the orofacial inflammation model showed that in rats the mRNA levels of
neuronal and glial activation markers changed parallel with the mechanical hyperalgesia in the TG,
TNC and PBMCs [49]. In contrast with rats, we could not unequivocally reproduce the results of the
activation marker changes in the mice, either. As mentioned before, there was already a difference
in the baseline expression of glial activation markers in intact mice between the two genotypes.
In the intact TG and TNC of Tac4-/- mice, there was a lower expression of the microglia/macrophage
marker Iba1 and the SGC/astrocyte marker Gfap was also expressed at a significantly lower level
in all the sampled tissues of Tac4-/- mice. The basal difference in activity is not entirely surprising
since macrophages are known to express both HK-1 and the NK-1 receptor and the Tac4 mRNA was
also detected in cultured microglia [36]. Likewise, previous data also revealed that astrocytes and
microglia in the brain express NK-1 receptors [110] and NK-1 receptor antagonist treatment could
reverse opioid withdrawal-induced astrocyte and microglia activation [111]. All activation markers
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increased significantly in both saline- and CFA-treated groups, which is most probably a consequence
of the injection procedure and the previously mentioned restraint-induced stress during the von Frey
threshold measurements. Both saline- and CFA-treated Tac4-/- mice had significantly lower levels of
FosB and Gfap upregulation compared to their respective WT counterparts. The marked difference
in Gfap between WT and Tac4-/- mice could also suggest that HK-1 plays a role in the activation of
SGCs and astrocytes during stress. Similarly, NK-1 receptor upregulation in astrocytes was linked to
stress-induced hyperalgesia and gastrointestinal motility disorders [112]. Nevertheless, compensatory
changes secondary to Tac4 deletion (e.g., expression changes of Tac1) cannot be excluded as factors
responsible for the observed differences.
Analysis of the Nanostring neuroinflammation panel kit data also revealed that there were
a number of differentially expressed genes between saline- or CFA-treated wild-type and Tac4-/-
mice. To our knowledge, this is the first such analysis in the TG to investigate neuroinflammation
in a pain model. The cell-type-specific profiling in the comparison of saline-treated wild-type and
Tac4-/- animals showed that microglia and cytotoxic cell-related genes were regulated in a significantly
different extent compared to other cell types involved in inflammatory processes. As we discussed
before, the effect of HK-1 deficiency on expression levels of macrophage/microglia-related genes is
expected due to the previously described distribution of both the peptide and the NK-1 receptor.
However, looking at individual differentially regulated genes, the functions of SGCs are also likely
to be affected. The most interesting finding among these genes is the downregulation of Kcnj10,
encoding the inwardly rectifying potassium channel subunit Kir4.1 in SGCs which has been linked to
inflammatory sensitization [63] and pain modulation by GABAB receptors [113]. Comparison of the
cell-type-specific profiling of differentially expressed genes between CFA-treated wild-type and Tac4-/-
mice only yielded a significant result in neutrophils. However, in the list of differentially expressed
genes, we have found various genes related to macrophage/microglia activity, neuronal transmission,
as well as genes mediating immune cell activation, such as calcineurin A or members of the Bcl-2
protein family, regulating apoptosis. Further validation of selected genes should be performed to
confirm their importance in the effects of HK-1 in the TG.
In summary, we conclude that HK-1 released from sensory neurons and satellite glial cells
may contribute to inflammatory processes and nociceptive sensitization underlying orofacial pain.
HK-1 is suggested to have a role in mediating neuron-glia interactions both under physiological and
inflammatory conditions. These results open interesting novel perspectives to identify the role and
mechanisms of action of HK-1 in neuroinflammation in other models of trigeminal sensitization and to
determine its potential clinical relevance.
4. Materials and Methods
4.1. Animals
Experiments were performed on male Wistar rats (Toxi-Coop, Hungary) weighing between
200–300 g, as well as on male, 8–12 week-old C57Bl/6 and Tac4-deficient (Tac4-/-) mice weighing between
20–25 g. The original breeding pairs of the Tac4-/- mice were generated as previously described [114].
Transgenic mice were generated on a C57Bl/6 background and backcrossed to homozygosity for >5
generations before using C57Bl/6 mice as controls, purchased from Charles River (Sulzfeld, Germany).
Animals were kept under standard light-dark cycle (12-h light/dark cycle) and temperature (22 ±
2 ◦C) conditions. Food and water were provided ad libitum, in the Animal House of the Department
of Pharmacology and Pharmacotherapy of the University of Pécs. All procedures were approved
by the National Ethics Committee on Animal Research of Hungary on 1 Aug 2017 (license No.:
BA02/2000-51/2017 issued on 22 Aug 2017 by the Government Office of Baranya County, Hungary)
and were performed according to the European legislation (Directive 2010/63/EU) and Hungarian
Government regulation (40/2013., II. 14.) on the protection of animals used for scientific purposes.
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4.2. CFA Injection
Orofacial inflammation in mice was induced by bilateral s.c. injection of 10–10 µL complete
Freund’s adjuvant (CFA; Sigma-Aldrich, Saint Louis, MI, USA; killed Mycobacteria suspended in
paraffin oil; 1 mg/mL) into the whisker pad under i.p. ketamine (100 mg/kg) and xylazine (5 mg/kg)
anaesthesia. In the case of rats, unilateral injection of 50 µL CFA was used, as previously described [49].
Control groups received the same volume of saline injection in both cases. We randomized the
treatment of animals within each cage, ensuring a similar sample size for each treatment group.
4.3. Orofacial Pain Sensitivity Tested with von Frey filaments
A set of calibrated nylon monofilaments (Stoelting, Wood Dale, Illinois, USA) was used to perform
measurements before and after CFA/saline injection on all animals. Increasing strengths (rats: 0.8–12 g,
mice: 0.0075–1 g) were used to measure facial mechanosensitivity. The mechanonociceptive threshold
was defined as the lowest force evoking at least 2 withdrawal responses (face stroking with the forepaw
or head shaking) out of 5 stimulations according to our previous paper [49]. The experimenter was not
blinded for these measurements as the visible inflammatory oedema of the whisker pad cannot be
hidden during the in vivo experiments.
4.4. Sample Collection
For RT-qPCR analysis, TG and TNC tissue and PBMC samples were collected from animals on day
1, 3, and 7 after receiving s.c. CFA injection and following behavioral tests. Animals were anaesthetized
with pentobarbital (rats: 50 mg/kg and mice 70 mg/kg i.p.) and sacrificed by exsanguination. TGs and
TNCs were excised and snap-frozen in liquid nitrogen.
For RNAscope, animals were transcardially perfused with 0.01 M phosphate-buffered saline (PBS;
pH 7.6) followed by 4% paraformaldehyde solution on day 3 after CFA or saline injections. TGs were
postfixed for 24 h at room temperature, rinsed in PBS, dehydrated, and embedded in paraffin using
standard procedures. 5 µm sections were cut using a sliding microtome (HM 430 Thermo Fisher
Scientific, Waltham, MA, USA).
TG samples for Nanostring analysis were snap-frozen on day 3 and stored at −80 ◦C until use.
RNAscope and Nanostring analysis were performed on samples derived from animals not involved in
behavioral studies. Samples were processed in a blinded manner.
4.5. RNAscope In Situ Hybridization (ISH)
RNAscope assay was performed on 5µm thick longitudinal TG sections using RNAscope Multiplex
Fluorescent Reagent Kit v2 (ACD, Hayward, CA, USA) according to the manufacturer’s instructions.
Briefly, tissue sections were baked, deparaffinized and H2O2-blocked, boiled, pretreated with Protease
Plus and hybridized with mouse Tac4, Kcnn3, Rbfox3, mouse 3-plex positive and negative control probes.
Signal amplification and channel development were applied sequentially. Nuclei were counterstained
with 4′,6-diamidino-2-phenylindole (DAPI) and mounted with ProLong Glass Antifade Mountant
for confocal imaging. Probes, applied dilutions of fluorophores are listed in Supplementary Table S1.
Fluorescent images were acquired using an Olympus Fluoview FV-1000 laser scanning confocal
microscope (Olympus, Tokyo, Japan) and Fluo-View FV-1000S-IX81 image acquisition software system.
The confocal aperture was set to 80 µm. The analogue sequential scanning was performed using a 40×
objective lens (NA: 0.75). The optical thickness was set to 1 µm and the resolution was 1024 × 1024 pixel.
The excitation time was set to 4 µs per pixel. Virtual colours were selected to depict fluorescent signals:
blue for DAPI, green for fluorescein (Polr2a), red for Cyanine 3 (Tac4 and Ppib) and white for Cyanine
5 (Ubc). Images of the respective four channels were stored both individually and superimposed to
evaluate the co-localization of fluorescent signals. Basal and elevated Tac4 expression levels were
analyzed semi-quantitatively using ImageJ software according to the manufacturer’s guideline in a
blinded-manner. On rat TG, Tac4 transcripts were quantified on Tac4-positive neurons and SGCs from
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CFA (neuron, n = 120; SGC, n = 69)-and saline (neuron, n = 68 SGC, n = 52)-treated animals, n = 4–6
rats/group. Similarly, on mouse TG, Tac4 transcripts were quantified on Tac4-positive neurons and
SGCs from CFA (neuron, n = 119; SGC, n = 54)-and saline (neuron, n = 71; SGC, n = 38)-treated animals,
n = 4–5 mice/group.
4.6. Mononuclear Cell Separation from Peripheral Blood
PBMCs were obtained by Ficoll-PaquePREMIUM (GE Healthcare, Budapest, Hungary) standard
density gradient centrifugation method [49]. Briefly, the mixture of fresh anticoagulant-treated blood,
pooled from 3 individual mice and an equal volume of balanced salt solution was carefully overlaid on
Ficoll-PaquePREMIUM and centrifuged. The mononuclear layer was transferred into a new tube and
washed twice with the salt solution. The supernatant was discarded, the cells were resuspended in TRI
Reagent (Zymo Research, Irvine, CA, USA) and stored at −80 ◦C until use.
4.7. Quantitative Real-Time PCR (RT-qPCR)
Total RNA purification, transcription and RT-qPCR from rat samples were performed exactly as
described previously [49]. In the case of samples from mice, the same protocol was used with minor
modifications as follows. TRI Reagent manufacturer’s (Zymo Research, Irvine, CA, USA) protocol was
followed up to the step of acquiring the aqueous phase. Further RNA purification was made from the
aqueous phase using the Direct-zol RNA MiniPrep kit (Zymo Research, Irvine, CA, USA) according to
the manufacturer’s protocol. Nanodrop ND-1000 Spectrophotometer V3.5 (Nano-Drop Technologies,
Inc., Wilmington, DE, USA) was used to define the quantity and purity of the extracted RNA. Total RNA
was reverse transcribed using Maxima First Strand cDNA Synthesis Kit (ThermoScientific, Santa Clara,
CA, USA), PCR amplification was performed using SensiFast SYBR Lo-ROX Kit (Bioline, Taunton,
MA, USA). From the enlisted reference genes: glyceraldehyde 3-phosphate dehydrogenase (Gapdh),
hypoxanthine phosphoribosyltransferase 1 (Hprt1), beta-2-microglobulin (β2m) and Peptidyl-prolyl
cis-trans isomerase (Ppia), after transcripts were detected in all samples, Ppia (TG) and Ppia, Gapdh
(PBMCs, TNC) were chosen as internal controls. Primers of similar efficiencies were used and 2−∆∆Cq
fold change values were calculated. All the primers used for RT-qPCR are listed in Supplementary
Table S2.
4.8. Nanostring
NanoString nCounter® technology (NanoString Technologies, Seattle, WA, USA) was used,
for expression profiling of RNA isolated from TG, according to the manufacturer’s instructions.
Mouse Neuroinflammation Panel was composed of probes for 770 genes related to immunity and
inflammation, neurobiology and neuropathology.
Total RNA isolation and purification from mouse TG samples were performed using TRI Reagent
and Direct-zol RNA MiniPrep kit as previously described, performing column DNase treatment as
well. The RNA quality and quantity were measured using Bioanalyzer 2100 (Agilent, Santa Clara,
CA, USA), Qubit Fluorometer Fluorescence Qubit 3.0 (ThermoFisher Scientific, Waltham, MA, USA)
and Nanodrop ND-1000 Spectrophotometer V3.5 (Nano-Drop Technologies, Inc., Wilmington, DE,
USA). Only samples with an RNA integrity number RIN >8.1 and 260/280 ratios of ∼2.0 were used for
further analysis.
The RNA samples (25 ng of each) were processed using Mus musculus Neuroinflammation
panel v1.0 according to the manufacturer instructions (user manual MAN-10023-11) on
NanoString SPRINT Profiler instrument. Analysis of data was performed using nCounter®
Advanced Analysis plugin v2.0.115 for the nSolver Analysis Software v4.0.70 with the
ProbeAnnotations_NS_Mm_NeuroInflam_v1.0 file provided by NanoString, using default settings.
Briefly, raw data with gene counts lower than 50 were removed, suitable reference genes were evaluated
using geNorm pairwise variation statistic, gene count data were normalized, differentially expressed
genes were determined and cell type profiling was performed for each comparison.
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Differentially expressed genes were plotted on heat maps where rows represent genes and columns
represent TG samples. Normalized gene counts data are shown as row-wise z-scores (scale is shown on
legend). Rows and columns were hierarchically clustered using Pearson correlation distance measure
and average method. Distances are shown as dendrograms. Clustering and heat map generation were
performed using the R language version 3.6.1 and the pheatmap package v1.0.12.
4.9. Statistical Analysis
GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA) was used for the statistical
analysis of behavioral data, RT-qPCR and RNAscope quantification. After testing datasets for normal
distribution, two-way analysis of variance (ANOVA) with repeated measures followed by Tukey’s
multiple comparison tests was performed for time-matching samples (behavioral studies). One-way
or two-way ANOVA followed by Tukey’s multiple comparison tests was used for RT-qPCR data.
Student’s t-test for unpaired samples was preferred for RNAscope analysis to compare saline- and
CFA-treated tissues. Sample numbers for each experiment are listed in Supplementary Table S3.
Results are plotted as the mean ± standard error of the mean (SEM). Probability values p ≤ 0.05 were
accepted as significant in all tests.
Analysis of NanoString data was performed using nCounter® Advanced Analysis Software
v2.0.115. Differentially expressed genes were determined by applying log-linear model (linear
regression) with a p-value threshold of 0.05. Correlation of cell-type marker genes was determined
with a threshold of p < 0.05 for each comparison.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/21/8/2938/s1.
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